Fujiwara and colleagues showed that in Cetuximab-treated oral HNSCC cells the therapeutic antibody was secreted within EGFR-containing vesicles (including exosomes and microvesicles), thereby providing evidence of a mechanism by which the release of EGFR-containing vesicles may reduce the antibody therapeutic efficacy (110). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.